TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ustekinumab to Evaluate a Subject-tailored Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Eligibility Criteria~* Male or female~* Have had a diagnosis of plaque-type psoriasis at least 6 months prior to the first administration of study agent (subjects with concurrent psoriatic arthritis may be enrolled).~* Have plaque-type psoriasis covering at least 10% of their total BSA at screening and at the time of the first administration of study agent.~* Have a PGA score of ≥ 3 at screening and at the time of the first administration of study agent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: Approved q12w maintenance regimen (Type: EXPERIMENTAL): Active ustekinumab study agent q12 weeks with sham/placebo as necessary to maintain blind
- Group 2: Subject-tailored fixed-interval maintenance regimen (Type: EXPERIMENTAL): Subjects will undergo placebo withdrawal and will receive active study agent up to q24w intervals with sham/placebo injections to maintain the blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exenatide and Metformin Therapy in Overweight Women With PCOS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:Overweight/obese women (BMI\>27)~1. Must have six or fewer menses /year or be amenorrheic~2. Have either clinical or laboratory evidence of hyperandrogenism (hirsutism or elevated testosterone (T)) and /or PCOS ovary on ultrasound~Exclusion Criteria:~other uncorrected endocrinopathy- hyperprolactinemia, hyper- or hypothyroidism, congenital adrenal hyperplasia or presence of overt diabetes alterations in hepatic or renal function use of hormonal medications, insulin sensitizers or medications that interfere with carbohydrate metabolism for at least 8 weeks Known active substance abuse including tobacco and alcohol. Pregnancy, breastfeeding or desire for pregnancy during study interval (6 months~-

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 12 / 48 Week Pivotal PFT vs PBO in COPD I

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* All patients must have a diagnosis of chronic obstructive pulmonary disease~* Male or female patients, 40 years of age or older Patients must be current or ex-smokers with a smoking history of more than 10 pack years Post bronchodilator FEV1 \<80% predicted and post-bronchodilator FEV1/FVC \<70%~Exclusion criteria:~* Patients with a significant disease other than COPD~* Patients with a history of asthma~* Patients with any of the following conditions:~a history of myocardial infarction within 1 year of screening visit (Visit 1) unstable or life-threatening cardiac arrhythmia. have been hospitalized for heart failure within the past year. known active tuberculosis a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed) a history of life-threatening pulmonary obstruction a history of cystic fibrosis

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olodaterol (BI 1744) Low (Type: EXPERIMENTAL): Low dose inhaled orally once daily from the Respimat inhaler
- Olodaterol (BI 1744) High (Type: EXPERIMENTAL): High dose inhaled orally once daily from the Respimat inhaler
- Placebo (Type: PLACEBO_COMPARATOR): Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Japanese P III vs Voglibose and Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. Japanese patients with a diagnosis of type 2 diabetes mellitus. Antidiabetic therapy has to be stable for at least 10 weeks before Visit 1.~2. Glycosylated haemoglobin A1 (HbA1c) 7.0 - 10.0% at Visit 3 (beginning of the 2-week placebo run-in phase)~3. Age: \>= 20 and \<= 80~4. Body Mass Index (BMI) \<= 40 kg/m2~Exclusion criteria:~1. Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months before Visit 1~2. Impaired hepatic function~3. History of severe allergy/hypersensitivity~4. Treatment with anti-diabetic, anti obesity drugs, etc 3 months before Visit 1~5. Fasting blood glucose \>240 mg/dl (=13.3 mmol/L) at Visits 2 or 3

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- voglibose 0.2 mg three times a day (TID) (Type: ACTIVE_COMPARATOR): patient to receive a tablet containing 0.2 mg voglibose TID plus 2 placebo tablets matching BI 1356
- BI 1356 low dose (Type: EXPERIMENTAL): patient to receive a tablet containing BI 1356 and matching placebo plus 3 placebo tablets matching voglibose
- BI 1356 high dose (Type: EXPERIMENTAL): patient to receive 2 tablets containing BI 1356 plus 3 placebo tablets matching voglibose
- placebo (Type: PLACEBO_COMPARATOR): patient to receive 2 placebo tablets matching BI 1356 plus 3 placebo tablets matching voglibose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* BMI in the range 22-45 and with a stable weight for the last 6 months~* Blood glucose criteria must be met~* Written informed consent~Exclusion Criteria:~* Pregnancy or lactation~* Previous diagnosis of type 2 diabetes or treatment with hypoglycemic agents~* Type 1 diabetes~* Evidence of cardiovascular complications as defined by the protocol~* Evidence of diabetic complications as defined by the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Ketorolac for Postsurgical Pain in Dental Implant Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Key Inclusion Criteria~1. Male or female between 18 and 64 years of age.~2. Must sign informed consent prior to initiation of any study procedures. The subject must be able to understand and agree to cooperate with study requirements.~3. BMI between 19 and 29 kg/m2.~4. Must require the surgical placement of 1 - 3 dental implants that are being placed in a one or two stage non-immediately loaded surgical procedure employing 2% lidocaine and/or 4% articaine with epinephrine and/or 3% mepivacaine plain for local anesthesia.~5. Females of child-bearing potential must have a negative urine pregnancy test at screening and immediately prior to the initiation of dental implant surgery and must have been using adequate means of birth control (abstinence, oral contraceptive steroids, intrauterine device (IUD), etc.) for at least one month prior to study entry and during the study.~6. In the opinion of the investigators the subject can safely tolerate ketorolac and acetaminophen.~   -~Exclusion Criteria:~Key Exclusion Criteria~1. Require the placement of more than 3 implants or require extensive bone grafting in addition to implant placement.~2. Need to administer anxiolytic/sedation drugs during surgery other than nitrous oxide/oxygen.~3. Need to administer the long acting local anesthetic bupivacaine with 1:200,000 epinephrine.~4. Implant(s) that are going to be immediately loaded on the day of surgery~5. Females that are pregnant or breast feeding~6. Allergies or hypersensitivity (aspirin sensitive asthma) to ketorolac, aspirin, ibuprofen, other NSAIDs, or acetaminophen.~7. History of gastrointestinal ulcers and/or bleeding.~8. On warfarin, dicumarol, clopidogrel or any other anticoagulant or antiplatelet therapy other than low dose (81 mg - 325 mg) aspirin.~9. Clinically significant kidney or liver disease where the intake of NSAIDs or acetaminophen would put the subject at undo risk.~10. Blood pressure greater than 160/95 at the time of screening or immediately before surgery.~11. Inflammation of the nasal mucosa or upper respiratory tract infection~12. Have ingested any analgesic agent within 48 hours of surgery.~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Ketorolac nasal spray 31.5 mg (Type: EXPERIMENTAL): Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ≥18 to ≤80 years of age~* History of T2DM for at least 6 months prior to screening~* Moderate to severe renal impairment and not actively on dialysis~* Willing and able to perform self-monitoring of blood glucose~* Willing and able to provide written informed consent~Exclusion Criteria:~* History of type 1 diabetes mellitus, diabetic ketoacidosis (within the previous 6 months), or diabetes resulting from pancreatic disorder or secondary diabetes (from acromegaly and/or Cushing's disease)~* Subjects who have received a renal allograft~* Subjects expecting to require dialysis or to undergo kidney transplantation within 3 months of study dosing~* Presence of active hepatic disease or clinically significant abnormal liver function tests at Screening or planned study Day -1~* Subjects with a history of heart attack, severe/unstable angina, or coronary revascularization procedure within 6 months prior to study Day -2~* History of clinically significant cardiac arrhythmias within 1 year prior to study Day -2~* Subjects with congestive heart failure~* Subjects with uncontrolled Stage III hypertension~* History of 2 or more emergency room visits, doctors' visits, or hospitalizations due to hypoglycemia within the 6 months prior to planned study Day -2~* History of alcohol or illicit drug abuse within 1 year prior to Screening~* History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C~* Major surgery within 6 months prior to planned study Day -2~* History of any malignancy within the last 5 years~* Triglycerides \>1000 mg/dL at Screening or planned study Day -1~* History of any serious adverse reaction or hypersensitivity to an SGLT inhibitor~* Use of corticosteroids within 2 weeks prior to study Day 1~* Use of any investigational drug within 30 days prior to study Day 1, or investigational protein or antibodies within 60 days of Day 1~* Positive urine pregnancy test at Screening~* Positive urine screen for illicit drug abuse at Screening~* Prior exposure to LX4211

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): None
- LX4211 Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Glycogen Liver Content Will Improve Post-operative Liver Function in Patients Undergoing Major Liver Resections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* planned to undergo a major liver resection at McGill University Health Center (MUHC)~Exclusion Criteria:~* patients known with chronic viral liver disease~* uncontrolled or type one diabetes mellitus (DM)~* patients on oral beta-blocker agents~* patients with unresectable disease determined intra-operatively~* patients unable to give consent for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: PLACEBO_COMPARATOR): Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
- GICP (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-75 years of age, of either sex or any race~* Clinical history of at least 2 lipomas for at least one year~* Lipomas diagnosed as benign~* Two lipomas on distinctly separate parts of the body, or on the torso if 30 cm apart, with easily definable edges~* Each lipoma is a single mass with easily definable edges~* Lipomas are 5 to 24 cm squared~* Women of childbearing potential must use an acceptable method of birth control~Exclusion Criteria:~* Lipomas on the head, neck, hand or foot, or female breast~* Women who are nursing or pregnant~* Multi-lobular lipomas~* Subjects who have received an investigational drug within 30 days before receiving the first dose of study drug in this study~* Subjects with a known allergy to collagenase or any of the inactive ingredients in XIAFLEX~* Subjects with uncontrolled diabetes, hypertension, or thyroid disease, or any medical condition that would make the subject unsuitable for enrollment~* Subjects having prior treatment or trauma of the lipoma that could interfere with study assessments~* Subjects with a history of connective tissue diseases, rheumatological diseases~* Subjects taking anticoagulants or planning to receive anticoagulants (except for lo dose aspirin and over-the-counter nonsteroidal anti-inflammatory drugs) within 7 days of injection of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- AA4500 (Type: ACTIVE_COMPARATOR): single injection of 0.58 mg study drug
- Placebo (Type: PLACEBO_COMPARATOR): single injection of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes mellitus~* Patients age 35-75~* Metabolic control of diabetes by diet or oral treatment (unmodified in the last 3 months)~* Blood pressure \<160/100 mmHg, including subjects with controlled hypertension, treated with ACE-inhibitors/sartans, unmodified in the last 3 months~Exclusion Criteria:~* Participation in another study with an investigational drug or device~* HbA1c \>12%~* Alterations during ECG stress examination~* Current use of nitrate agents~* Proliferative retinopathy~* Patients with history of cardiovascular and malignant disease~* Psychosocial disturbance~* Alcohol or drug dependence~* Allergy or hypersensitivity to sildenafil or other Phosphodiesterase inhibitors.

- Gender: MALE
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Sildenafil 100 mg
- 2 (Type: PLACEBO_COMPARATOR): Placebo 100 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with dementia of the Alzheimer's type, mixed dementia, or vascular dementia, (as classified by the Diagnostic and Statistical Manual of Mental Diseases, 4th edition \[DSM-IV\]) and have behavioral disturbances~* a score \>=4 on the FAST~* a score \<=23 on the MMSE~* a BEHAVE-AD total score \>=8, and a BEHAVE-AD global rating \>=1~* must be institutionalized.~Exclusion Criteria:~* Patients with other medical or neurological conditions in which cognition (thinking, perception, learning, verbal communication, memory, judgment) is diminished (for example, drug overdosage, severe liver, heart, lung, and kidney malfunctions, Parkinson's disease)~* other psychiatric disorders, including major depression, schizophrenia, substance abuse or dependence~* abnormal electrocardiogram (ECG) findings~* abnormal clinical laboratory test findings.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Medicine Intervention With Depressed Patients in a Community Health Center Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 21 years of age or older~* Diagnosis of depression~* Currently being treated for depression with medications and/or psychological counseling through one of the MGH-HealthCare Centers.~* Planning to continue using the health center as their main source of general medical services for the coming year.~Exclusion Criteria:~* History of bipolar disorder~* Active substance abuse~* History of psychosis~* Severe cognitive dysfunction (MMSE ≤ 24)~* Inability to speak English~* We will not exclude patients on the basis of their religious preferences or practices.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Relaxation Response Resiliency Program for Depression (Type: EXPERIMENTAL): The Relaxation Response Resiliency Program for Depression (3RP-D) is a low-cost, easily replicable, 6-session, 1.5 hour, mind body intervention.~The 3RP-D was designed to promote resiliency by reducing the harmful effects of stress through the elicitation of the relaxation response, and through skill training to enhance positive attitudes and beliefs, nutrition, exercise, recuperative sleep, social support, and coping. Specific interventions include: cognitive behavioral therapy (CBT), enhancing social support (SS), cultivating positive attitudes and beliefs (CPE), and promoting Healthy Lifestyle Habits(HL). The 3RP-D program has been manualized for use by group facilitators and health center patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intensified Physical Activity for Patients With Stroke - a Combined Physical and Behavioural Approach

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with first-ever stroke in the age of 65-65 years getting their stroke at least one year ago and living in the community.~Exclusion Criteria:~* Other illness or disability that have an impact on the activity level and participation in tests beside problems after stroke.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: NO_INTERVENTION): Participants in the control group are instructed to live their ordinary life.
- Intervention group (Type: EXPERIMENTAL): Exercising two times/week according to the High-Intensity Functional Exercise Program (HIFE) in groups of 5-7 patients in combination with motivational discussions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least 10 years of age \& either sex, any race~* Willing and able to follow all instructions and attend all study visits~* Positive history of ocular allergies~Exclusion Criteria:~* Have planned surgery during trial period~* Female currently pregnant, planning a pregnancy, or lactating

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bepreve (Type: EXPERIMENTAL): Bepotastine Besilate Ophthalmic Solution 1.5%
- Placebo (Type: PLACEBO_COMPARATOR): sterile ophthalmic solution
- Bepotastine Besilate (Type: EXPERIMENTAL): sterile ophthalmic solution 1.0%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete